Intrahepatic cholestasis: Summary of an American Association for the Study of Liver Diseases single‐topic conference
William F. Balistreri, Jorge A. Bezerra, Peter Jansen, Saul J. Karpen, Benjamin L. Shneider, Frederick J. Suchy – 16 May 2005
Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study
Giorgio Bedogni, Lucia Miglioli, Flora Masutti, Claudio Tiribelli, Giulio Marchesini, Stefano Bellentani – 13 May 2005 – The prevalence of and the risk factors for fatty liver have not undergone a formal evaluation in a representative sample of the general population. We therefore performed a cross‐sectional study in the town of Campogalliano (Modena, Italy), within the context of the Dionysos Project. Of 5,780 eligible persons aged 18 to 75 years, 3,345 (58%) agreed to participate in the study.
Purification and characterization of mouse fetal liver epithelial cells with high in vivo repopulation capacity
Dirk Nierhoff, Atsushi Ogawa, Michael Oertel, Yuan‐Qing Chen, David A. Shafritz – 13 May 2005 – Epithelial cells in embryonic day (ED) 12.5 murine fetal liver were separated from hematopoietic cell populations using fluorescence‐activated cell sorting (FACS) and were characterized by immunocytochemistry using a broad set of antibodies specific for epithelial cells (α‐fetoprotein [AFP], albumin [ALB], pancytokeratin [PanCK], Liv2, E‐cadherin, Dlk), hematopoietic/endothelial cells (Ter119, CD45, CD31), and stem/progenitor cells (c‐Kit, CD34, Sca‐1).
Safety of short‐term administration of celecoxib in decompensated cirrhosis
Mical S. Campbell, George A. Makar – 12 May 2005
Influence of tips on development of hepatocellular carcinoma in cirrhosis
Louis Libbrecht, Geert Maleux, Chris Verslype, Frederik Nevens, Tania Roskams – 12 May 2005
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
Christophe Hézode, Françoise Roudot‐Thoraval, Son Nguyen, Pascale Grenard, Boris Julien, Elie‐Serge Zafrani, Jean‐Michel Pawlostky, Daniel Dhumeaux, Sophie Lotersztajn, Ariane Mallat – 12 May 2005 – Cannabinoids present in Cannabis sativa (marijuana) exert biological effects via cannabinoid receptors CB1 and CB2. We recently demonstrated that CB1 and CB2 receptors regulate progression of experimental liver fibrosis. We therefore investigated the impact of cannabis smoking on fibrosis progression rate in patients with chronic hepatitis C (CHC).
Reply:
Shruti Mehta, David Thomas, Mark Sulkowski – 6 May 2005
Antiretroviral therapy and liver fibrosis in HIV‐infected patients with chronic hepatitis C
Juan Macías, José A. Mira, Salvador Vergara, Juan A. Pineda – 2 May 2005
Nonischemic cardiomyopathy after orthotopic liver transplantation: A report of three cases and a review of the literature
Kenneth S. Stewart, Chun H. Rhim, Michelle L. Bahrain, Zahra D. Ashkezari, Metin Ozdemirli, Thomas M. Fishbein, Lynt B. Johnson, Amy D. Lu, Jeffrey S. Plotkin – 21 April 2005 – In 2002 there were more than 5,000 liver transplantations performed in the United States. As of February 2004 there were more than 17,000 registrations for liver transplantation. As more organs are transplanted and surgical techniques improve, unique causes of morbidity and mortality will become apparent.
MELD—Moving steadily towards equality, equity, and fairness
James Neuberger, Douglas Thorburn – 21 April 2005 – Background and aims: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. Our aim was to assess the capability of the Model for End‐Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list.